Investment Overview - SK Capital Partners' affiliate has agreed to invest in Swixx BioPharma, valuing the company at over €1.5 billion ($1.76 billion) [1] - The investment aims to support Swixx's next stage of growth and international expansion [1] Company Operations - Swixx operates as a commercialization platform for pharmaceutical companies, focusing on markets that these companies have chosen not to enter or have exited [1] - The company's mission is to provide access to essential medications in hard-to-reach and underserved regions [1] Market Presence - Swixx's footprint includes Greece, Central and Eastern Europe, Eurasia, several Commonwealth of Independent States (CIS) countries, Latin America, and the Middle East [2] - Sales are anticipated to exceed €1.3 billion in 2026 [2] Ownership and Management - Co-founders Stuart Swanson and Petr Němec, along with CEO Jean-Michel Lespinasse and CFO Petr Pipal, will maintain significant ownership stakes post-investment [2] - Current institutional investors HBM Healthcare Investments and Mérieux Equity Partners will also remain as shareholders [3] Strategic Goals - Lespinasse emphasized that the partnership is a pivotal moment for Swixx, bringing additional capital and expertise to drive growth [3] - The company is committed to expanding its role as a trusted partner for leading global biopharmaceutical companies, delivering sustainable outsourcing solutions in complex and emerging markets [4] Advisory and Support - Rothschild & Co is acting as SK Capital's sole financial advisor, with legal counsel provided by Bär & Karrer and Kirkland & Ellis [4] - KPMG advised on tax, financial, compliance, and IT due diligence, while ClearView Healthcare Partners supported commercial due diligence [5] - Ares Credit funds provided committed debt financing for the deal [5] - On Swixx's side, Jefferies served as lead financial advisor, with Centerview Partners also acting as a financial advisor and Walder Wyss providing legal counsel [5] Asset Management - As of December 31, 2024, SK Capital manages close to $10 billion in assets [6]